Emfogen
Generic Name
Empagliflozin 25 mg
Manufacturer
Square Pharmaceuticals Ltd.
Country
Bangladesh
Loading images...
Price Details
Current market pricing information
| Variant | Unit Price | Strip Price |
|---|---|---|
| emfogen 25 mg tablet | ৳ 40.00 | ৳ 400.00 |
Description
Overview of the medicine
Emfogen 25 mg tablet contains Empagliflozin, which is used to treat type 2 diabetes mellitus, heart failure with reduced ejection fraction, and chronic kidney disease.
Uses & Indications
Dosage
Adults
The recommended starting dose is 10 mg once daily. If additional glycemic control is needed and the 10 mg dose is tolerated, the dose can be increased to 25 mg once daily. For heart failure and chronic kidney disease, the recommended dose is 10 mg once daily.
Elderly
No dosage adjustment is required based on age; however, monitor renal function.
Renal_impairment
For type 2 diabetes, empagliflozin is not recommended for glycemic control in patients with eGFR <30 mL/min/1.73m². For heart failure and chronic kidney disease, it can be initiated in patients with eGFR ≥20 mL/min/1.73m².
How to Take
Take orally once daily in the morning, with or without food. Swallow the tablet whole with water.
Mechanism of Action
Empagliflozin is a selective inhibitor of sodium-glucose co-transporter 2 (SGLT2). By inhibiting SGLT2, it reduces reabsorption of filtered glucose in the kidney and lowers the renal threshold for glucose, leading to increased urinary glucose excretion.
Pharmacokinetics
Onset
Within hours (glucose lowering effect).
Excretion
Approximately 50% renally excreted and 50% fecally excreted.
Half life
Approximately 10-13 hours.
Absorption
Rapidly absorbed after oral administration, peak plasma concentrations reached in 1.5 hours. Absolute bioavailability is approximately 78%.
Metabolism
Primarily metabolized by glucuronidation via UDP-glucuronosyltransferases (UGTs) UGT1A3, UGT1A8, UGT1A9, and UGT2B7.
Side Effects
Contraindications
- Hypersensitivity to empagliflozin or any excipients.
- Severe renal impairment (eGFR <30 mL/min/1.73m² for glycemic control in T2DM), end-stage renal disease, or patients on dialysis.
Drug Interactions
Diuretics
May increase the risk of dehydration and hypotension.
ACE Inhibitors / Angiotensin Receptor Blockers (ARBs)
Potentially increased risk of hypotension, especially in volume-depleted patients.
Insulin and Insulin Secretagogues (e.g., sulfonylureas)
May increase the risk of hypoglycemia. A lower dose of insulin or sulfonylurea may be required.
Storage
Store below 30°C in a dry place, away from light and moisture. Keep out of reach of children.
Overdose
Overdose may lead to increased urinary glucose excretion, dehydration, and hypotension. Treatment is supportive, including rehydration and monitoring of vital signs.
Pregnancy & Lactation
Not recommended during the second and third trimesters of pregnancy due to potential adverse renal effects on the fetus. Not recommended during breastfeeding due to potential risk to the infant.
Frequently Asked Questions
Common questions about this medicine
Pack Sizes
Shelf Life
36 months
Availability
Pharmacies, Hospitals
Approval Status
Approved (FDA, DGDA)
Patent Status
Under patent protection
WHO Essential Medicine
YesClinical Trials
Empagliflozin has been evaluated in extensive clinical trials including EMPA-REG OUTCOME (cardiovascular outcomes), EMPEROR-Reduced and EMPEROR-Preserved (heart failure), and EMPA-KIDNEY (chronic kidney disease).
Lab Monitoring
- Renal function (eGFR) before initiation and periodically during treatment.
- Glycemic control (HbA1c).
- Lipid panel (periodically).
- Urine ketones (if symptoms suggestive of ketoacidosis).
Doctor Notes
- Monitor eGFR before initiation and periodically.
- Assess patient for risk factors of DKA (e.g., insulin deficiency, reduced caloric intake, acute illness) before and during treatment.
- Advise patients on symptoms of UTIs and genital mycotic infections and when to seek medical attention.
Patient Guidelines
- Take Emfogen 25 mg tablet exactly as prescribed by your doctor.
- Stay well-hydrated, especially in hot weather or during illness, to prevent dehydration.
- Be aware of the symptoms of urinary tract infections (UTIs) and genital yeast infections, and report them to your doctor.
- Monitor your blood sugar regularly as advised by your healthcare provider.
Missed Dose Advice
If you miss a dose, take it as soon as you remember. If it is almost time for your next dose, skip the missed dose and continue your regular dosing schedule. Do not take a double dose to make up for a missed one.
Driving Precautions
Emfogen may cause dizziness or lightheadedness, especially when starting treatment or if combined with other medications that lower blood sugar. Exercise caution when driving or operating machinery.
Lifestyle Advice
- Follow a balanced diet plan recommended by your doctor or dietitian.
- Engage in regular physical activity as appropriate.
- Maintain good personal hygiene, particularly genital hygiene, to reduce the risk of infections.
Alternative Medicines in Bangladesh
Similar medicines available in the market
Global Brand Names
International brand names for this medicine. Click a brand to search for detailed information.